Can a chemical found in citrus fruit curb cancer and save lives through early detection? Today on the show, we'll talk about the possibilities with Dr. David Suhy, Cofounder and Chief Medical Officer of Earli. Earli was founded with the mission to make cancer a benign experience by catching and curing it early. According the the American Cancer Society, 40% of people will be diagnosed with cancer at some point in their lifetime. And a third will die from it. What if there was a way to detect and confirm the presence of cancer by inducing synthetic biomarkers? You could catch cancer when it's most treatable and save countless lives. Learn more about this exciting technology and get inspired by David's insights. About David Suhy Dr. David Suhy is the Chief Scientific Officer and Cofounder of Earli. He is a gene therapy expert, experienced in bio ventures both private and public. He has led gene therapy ideas from inception through Phase 2 clinical trials, and is recognized as a leader that science teams love to work with. Before Earli, he was the CSO at Benitec Biopharma where he oversaw development paths for products in or near term clinical studies, including Hepatitis C Virus (HCV), Head and Neck Squamous Cell Carcinoma (HNSCC), and Oculopharyngeal Muscular Dystrophy (OPMD). He developed the first non-withdrawable, systemic RNAi compound used clinically in human subjects. He previously held scientific leadership roles at Tacere Therapeutics, Takara Bio, Anatara and PPD.  He earned his PhD in Biochemistry, Molecular Biology and Cell Biology  from Northwestern University and completed his post doctoral training at Stanford University. He's a father to three teenagers, and he loves making pizza in his large wood-fired oven in his backyard. David is married to a neuroscientist, Dr. Joyce Suhy, who knows the risks of science, and is convinced that with David’s passion, Earli will accomplish its purpose. About Earli Earli was founded in June of 2018 by Dr. Sam Gambhir, Cyriac Roeding and Dr. David Suhy. Earli is developing  a technique, originally from Stanford University, to trigger the production of synthetic biomarkers as a means to detect, target and destroy cancer cells. Earli is currently enrolling for their clinical trial in Australia.  Links David Suhy | LinkedIn: https://www.linkedin.com/in/davidsuhy Earli: https://www.earli.com Earli Clinical Trial News: https://bit.ly/3A3bQ53 Sam Gambhir | Wikipedia: https://en.wikipedia.org/wiki/Sanjiv_Sam_Gambhir Qualio website: https://www.qualio.com/ Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez